{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:48:09Z","timestamp":1791136089297,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1016\/j.atherosclerosis.2007.09.019","type":"journal-article","created":{"date-parts":[[2007,12,4]],"date-time":"2007-12-04T17:15:53Z","timestamp":1196788553000},"page":"39-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":135,"title":["Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR\u2212\/\u2212 mice despite severe hypercholesterolemia"],"prefix":"10.1016","volume":"198","author":[{"given":"Marc A.","family":"Mueller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Beutner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Teupser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Ceglarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Thiery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2014an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib2","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.1365-2796.2000.00654.x","article-title":"Changing concepts of atherogenesis","volume":"247","author":"Libby","year":"2000","journal-title":"J Intern Med"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/3-540-27661-0_13","article-title":"Lipid and non-lipid effects of statins","author":"Paoletti","year":"2005","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib4","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1055\/s-2004-869592","article-title":"Lipid lowering therapy in atherosclerosis","volume":"4","author":"Aikawa","year":"2004","journal-title":"Semin Vasc Med"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib5","first-page":"1906","article-title":"Accelerated atherosclerosis in hyperlipidemic C57BL\/6 mice treated with cyclosporin A","volume":"142","author":"Emeson","year":"1993","journal-title":"Am J Pathol"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib6","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1172\/JCI118174","article-title":"Enhanced development of atherosclerosis in cholesterol-fed rabbits by suppression of cell-mediated immunity","volume":"96","author":"Roselaar","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0021-9150(95)05539-9","article-title":"Cyclosporine treatment reduces early atherosclerosis in the cholesterol-fed rabbit","volume":"116","author":"Drew","year":"1995","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0021-9150(99)00458-X","article-title":"Mycophenolate mofetil treatment reduces cholesterol-induced atherosclerosis in the rabbit","volume":"152","author":"Romero","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib9","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1034\/j.1600-6143.2002.20902.x","article-title":"Cardiovascular toxicities of immunosuppressive agents","volume":"2","author":"Miller","year":"2002","journal-title":"Am J Transplant"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib10","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1172\/JCI119038","article-title":"Rapamycin inhibits vascular smooth muscle cell migration","volume":"98","author":"Poon","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib11","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2165\/00003495-200464080-00005","volume":"64","author":"Chapman","year":"2004","journal-title":"Everolimus. Drugs"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib12","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa012843","article-title":"A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization","volume":"346","author":"Morice","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib13","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1001\/jama.294.7.819","article-title":"Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials","volume":"294","author":"Kastrati","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib14","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa066633","article-title":"A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents","volume":"356","author":"Spaulding","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib15","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1016\/j.transproceed.2003.10.050","article-title":"Effect of sirolimus on the cholesterol content of aortic arch in ApoE knockout mice","volume":"35","author":"Basso","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.atherosclerosis.2003.09.003","article-title":"Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1-independent pathway","volume":"172","author":"Castro","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib17","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/01.fjc.0000177985.14305.15","article-title":"Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis","volume":"46","author":"Pakala","year":"2005","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib18","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1161\/01.ATV.0000194096.89476.73","article-title":"Macrophage apolipoprotein E reduces atherosclerosis and prevents premature death in apolipoprotein E and scavenger receptor-class BI double-knockout mice","volume":"26","author":"Yu","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib19","first-page":"762","article-title":"The pleiotropic effects of mTor inhibitors","volume":"17","author":"Ponticelli","year":"2004","journal-title":"J Nephrol"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.critrevonc.2005.03.012","article-title":"Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy","volume":"56","author":"Taylor","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib21","doi-asserted-by":"crossref","unstructured":"Dann SG, Thomas G. The amino acid sensitive TOR pathway from yeast to mammals. FEBS Lett. 2006.","DOI":"10.1016\/j.febslet.2006.04.068"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib22","doi-asserted-by":"crossref","first-page":"495S","DOI":"10.1016\/j.transproceed.2004.01.015","article-title":"The evolving experience using everolimus in clinical transplantation","volume":"36","author":"Formica","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib23","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa022171","article-title":"Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients","volume":"349","author":"Eisen","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib24","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jacc.2006.09.047","article-title":"Selective clearance of macrophages in atherosclerotic plaques by autophagy","volume":"49","author":"Verheye","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib25","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1161\/01.ATV.0000090126.34881.B1","article-title":"Induction of atherosclerosis by low-fat, semisynthetic diets in LDL receptor-deficient C57BL\/6J and FVB\/NJ mice: comparison of lesions of the aortic root, brachiocephalic artery, and whole aorta (en face measurement)","volume":"23","author":"Teupser","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib26","doi-asserted-by":"crossref","first-page":"17795","DOI":"10.1073\/pnas.0408096101","article-title":"Major reduction of atherosclerosis in fractalkine (CX3CL1)-deficient mice is at the brachiocephalic artery, not the aortic root","volume":"101","author":"Teupser","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib27","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0021-9150(87)90202-4","article-title":"Quantitative assessment of atherosclerotic lesions in mice","volume":"68","author":"Paigen","year":"1987","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib28","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1161\/01.ATV.20.5.1177","article-title":"Natural history and histological classification of atherosclerotic lesions: an update","volume":"20","author":"Stary","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib29","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1161\/01.ATV.14.1.141","article-title":"Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression","volume":"14","author":"Reddick","year":"1994","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib30","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.cca.2006.05.019","article-title":"Inclusion of MPA and in a rapid multi-drug LC-tandem mass spectrometric method for simultaneous determination of immunosuppressants","volume":"373","author":"Ceglarek","year":"2006","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib31","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1034\/j.1600-6143.2003.00094.x","article-title":"Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice","volume":"3","author":"Elloso","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib32","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/jps.20751","article-title":"The pharmacodynamic effects of sirolimus and sirolimus-calcineurin inhibitor combinations on macrophage scavenger and nuclear hormone receptors","volume":"96","author":"Mathis","year":"2007","journal-title":"J Pharm Sci"},{"issue":"Suppl 3","key":"10.1016\/j.atherosclerosis.2007.09.019_bib33","doi-asserted-by":"crossref","first-page":"iii18","DOI":"10.1093\/ndt\/gfl300","article-title":"Everolimus in clinical practice\u2014renal transplantation","volume":"21","author":"Pascual","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib34","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1517\/13543784.11.12.1845","article-title":"Review of the proliferation inhibitor everolimus","volume":"11","author":"Nashan","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib35","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1016\/S0041-1345(00)01884-4","article-title":"Apolipoprotein CIII is upregulated by anticalcineurins and rapamycin: implications in transplantation-induced dyslipidemia","volume":"32","author":"Tur","year":"2000","journal-title":"Transplant Proc"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib36","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1097\/00007890-200110150-00011","article-title":"Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients","volume":"72","author":"Hoogeveen","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib37","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1023\/B:DDAS.0000011598.15105.58","article-title":"Everolimus\/cyclosporine interactions on bile flow and biliary excretion of bile salts and cholesterol in rats","volume":"49","author":"Deters","year":"2004","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib38","first-page":"951","article-title":"Synthesis of IL-1 alpha and IL-1 beta by arterial cells in atherosclerosis","volume":"138","author":"Moyer","year":"1991","journal-title":"Am J Pathol"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib39","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/S0024-3205(98)00470-6","article-title":"Chemokine production and adhesion molecule expression by neural cells exposed to IL-1, TNF alpha and interferon gamma","volume":"63","author":"Chuluyan","year":"1998","journal-title":"Life Sci."},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib40","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1161\/01.ATV.19.3.734","article-title":"The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice","volume":"19","author":"Lee","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib41","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0002-9440(10)63471-2","article-title":"The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice","volume":"163","author":"Davenport","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.atherosclerosis.2007.09.019_bib42","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1161\/01.CIR.0000033973.06059.04","article-title":"Oral everolimus inhibits in-stent neointimal growth","volume":"106","author":"Farb","year":"2002","journal-title":"Circulation"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915007005576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915007005576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:30:34Z","timestamp":1758155434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915007005576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S0021915007005576"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2007.09.019","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR\u2212\/\u2212 mice despite severe hypercholesterolemia","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2007.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}